|

Mid-afternoon market update: Dow tumbles over 200 points, BELLUS Health shares spike higher

Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 50,801,450 cases with around 817,950 deaths. India confirmed a total of at least 34,697,860 cases and 475,630 deaths, while Brazil reported over 22,189,860 COVID-19 cases with 616,940 deaths. In total, there were at least 270,510,600 cases of COVID-19 worldwide with more than 5,324,320 deaths.

Leading and Lagging Sectors

Real estate shares climbed 1.4% on Monday. Meanwhile, top gainers in the sector included Condor Hospitality Trust, Inc. CDOR +8.17% (Get Free Alerts for CDOR), up 8% and Nam Tai Property Inc. NTP +7.13% (Get Free Alerts for NTP) up 6%.

In trading on Monday, energy shares fell 2.5%.

Top Headline

Pfizer Inc PFE +4.62% agreed to acquire Arena Pharmaceuticals Inc ARNA +80.38%, a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.

Under the agreement terms, Pfizer will acquire Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

Equities Trading UP

Arena Pharmaceuticals, Inc. ARNA +80.38% shares shot up 80% to $89.80. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.

Shares of BELLUS Health Inc. BLU +48.21% got a boost, shooting 52% to $8.49 after the company announced topline data from its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. The data showed that the 50 mg and 200 mg BID doses of BLU-5937 achieved statistical significance on the primary endpoint with a 34% placebo-adjusted reduction in 24-hour cough frequency observed at day 28. 

Foghorn Therapeutics Inc. FHTX +54.96% shares were also up, gaining 34% to $16.05. Loxo Oncology, an R&D group of Eli Lilly And Co LLY +1.87%, and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.

Equities Trading DOWN

Nisun International Enterprise Development Group Co., Ltd NISN -60.29% shares tumbled 60% to $4.42 after the company priced its $77 million underwritten public offering of common shares and pre-funded warrants to purchase common shares.

Shares of IGM Biosciences, Inc. IGMS -41.31% were down 46% to $26.88 after reporting Phase 1 trial data in advanced B-Cell malignancies. RBC Capital downgraded IGM Biosciences to Sector Perform from Outperform with a price target of $51, down from $90.

Blonder Tongue Laboratories, Inc. BDR -30.8% was down, falling 31% to $0.60 after the NYSE American said it will commence delisting proceedings against Blonder Tongue Laboratories.

Commodities

In commodity news, oil traded down 0.1% to $71.64, while gold traded up 0.2% to $1,789.10.

Silver traded up 0.6% Monday to $22.325 while copper rose 0.1% to $4.2870.

Euro zone

European shares closed lower today. The eurozone’s STOXX 600 slipped 0.43%, the Spanish Ibex Index fell 0.45% and the German DAX 30 slipped 0.01%. Meanwhile, the London’s FTSE 100 fell 0.83%, French CAC 40 fell 0.70% and Italy’s FTSE MIB fell 0.64%.

Wholesale prices in Germany surged 16.6% year-over-year in November following a 15.2% increase a month ago.

Economics

There were no major US economic releases Monday.

Author

Benzinga Team

Benzinga's news desk is a dynamic and innovative team that provides real-time, actionable articles that help readers navigate the market.

More from Benzinga Team
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD flatlines below 1.1800 amid trading lull, awaits Fed Minutes

EUR/USD trades around a flatline below 1.1800 in European trading on Tuesday. The pair lacks any trading impetus as the US Dollar moves little amid market caution ahead of the Fed's December Meeting Minutes release, which could offer insights into the Federal Reserve’s 2026 outlook.

GBP/USD retakes 1.3500 despite the year-end grind

GBP/USD finds fresh demand and retakes 1.3500 on Tuesday as markets grind through the last trading week of the year. Despite the latest uptick, the pair is unlikely to see further progress due to the year-end holiday volumes.

Gold holds the bounce on Fed rate cut bets, safe-haven flows

Gold holds the rebound near $4,350 in the European trading hours on Tuesday. The precious metal recovers some lost ground after falling 4.5% in the previous session, which was Gold's largest single-day loss since October. Increased margin requirements on gold and silver futures by the Chicago Mercantile Exchange Group, one of the world’s largest trading floors for commodities, prompted widespread profit-taking and portfolio rebalancing.

Tron steadies as Justin Sun invests $18 million in Tron Inc.

Tron (TRX) trades above $0.2800 at press time on Monday, hovering below the 50-day Exponential Moving Average (EMA) at $0.2859.

Economic outlook 2026-2027 in advanced countries: Solidity test

After a year marked by global economic resilience and ending on a note of optimism, 2026 looks promising and could be a year of solid economic performance. In our baseline scenario, we expect most of the supportive factors at work in 2025 to continue to play a role in 2026.

Crypto market outlook for 2026

Year 2025 was volatile, as crypto often is.  Among positive catalysts were favourable regulatory changes in the U.S., rise of Digital Asset Treasuries (DAT), adoption of AI and tokenization of Real-World-Assets (RWA).